Negative News SentimentNegative NewsNASDAQ:VYNE VYNE Therapeutics (VYNE) Stock Price, News & Analysis $28.32 -0.24 (-0.82%) Closing price 07/27/2026Extended Trading$28.32 0.00 (0.00%) As of 07/27/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About VYNE Therapeutics Stock (NASDAQ:VYNE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VYNE Therapeutics alerts:Sign Up Key Stats Today's Range$23.37▼$28.5650-Day Range$25.45▼$46.1752-Week Range$14.03▼$79.75Volume93,278 shsAverage Volume44,151 shsMarket Capitalization$18.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates. The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation. VTX-002 is in IND-enabling studies for indications such as pulmonary fibrosis and other fibrotic disorders. A second discovery program is focused on a novel mechanism of complement modulation, intended to dampen excessive inflammatory responses in vascular and autoimmune diseases. In addition to these core assets, VYNE maintains a discovery engine aimed at identifying new small molecules with optimized drug-like properties for indications in cardiometabolic and fibrotic pathology. Since its founding, VYNE Therapeutics has built a leadership team comprised of seasoned executives and scientific founders with prior experience at leading biotechnology and pharmaceutical companies. The company collaborates with academic institutions and contract research organizations to accelerate preclinical and clinical activities. VYNE’s research and development efforts are designed to serve patient populations across North America and Europe, with strategic plans to expand into additional regions through partnerships and licensing agreements.AI Generated. May Contain Errors. Read More VYNE Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreVYNE MarketRank™: VYNE Therapeutics scored higher than 5% of companies evaluated by MarketBeat, and ranked 891st out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingVYNE Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVYNE Therapeutics has received no research coverage in the past 90 days.Read more about VYNE Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of VYNE Therapeutics is -74.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VYNE Therapeutics is -74.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVYNE Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.57% of the float of VYNE Therapeutics has been sold short.Short Interest Ratio / Days to CoverVYNE Therapeutics has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VYNE Therapeutics has recently increased by 76.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVYNE Therapeutics does not currently pay a dividend.Dividend GrowthVYNE Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News SentimentVYNE Therapeutics has a news sentiment score of -3.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for VYNE Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for VYNE on MarketBeat in the last 30 days. MarketBeat Follows1 people have added VYNE Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.03% of the stock of VYNE Therapeutics is held by insiders.Percentage Held by Institutions83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VYNE Therapeutics' insider trading history. Receive VYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VYNE Stock News HeadlinesVYNE Therapeutics (VYNE) Projected to Post Earnings on ThursdayAugust 6, 2026 | americanbankingnews.comGuardian Pharmacy Services (NYSE:GRDN) versus VYNE Therapeutics (NASDAQ:VYNE) Critical ContrastAugust 3, 2026 | americanbankingnews.comCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan is now targeting $4,900. One $15 fund is converting gold's momentum into up to $1,152 per month in payouts. No miners, no active trading - just monthly income.August 14 at 1:00 AM | Investors Alley (Ad)Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101July 29, 2026 | finance.yahoo.comYarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves ...July 27, 2026 | finance.yahoo.comVYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow BioscienceJuly 23, 2026 | globenewswire.comVYNE Therapeutics Inc.: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with ...July 22, 2026 | finanznachrichten.deVYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow BioscienceJuly 21, 2026 | globenewswire.comSee More Headlines VYNE Stock Analysis - Frequently Asked Questions How have VYNE shares performed this year? VYNE Therapeutics' stock was trading at $29.0050 at the beginning of the year. Since then, VYNE stock has decreased by 2.3% and is now trading at $28.3250. How were VYNE Therapeutics' earnings last quarter? VYNE Therapeutics Inc. (NASDAQ:VYNE) released its quarterly earnings data on Thursday, August, 13th. The company reported ($3.51) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $3.33. The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative trailing twelve-month return on equity of 70.42%. When did VYNE Therapeutics' stock split? VYNE Therapeutics's stock reverse split on the morning of Monday, February 13th 2023.The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did VYNE Therapeutics IPO? VYNE Therapeutics (VYNE) raised $116 million in an IPO on Thursday, January 25th 2018. The company issued 7,000,000 shares at $16.00-$17.00 per share. Who are VYNE Therapeutics' major shareholders? Top institutional investors of VYNE Therapeutics include ADAR1 Capital Management LLC (440.30%), GSA Capital Partners LLP (10.68%) and BlackRock Inc. (6.63%). View institutional ownership trends. How do I buy shares of VYNE Therapeutics? Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VYNE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VYNE Therapeutics investors own include NIO (NIO), Tesla (TSLA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA). Company Calendar Record date for 7/23 Dividend7/22/2026Dividend Payable7/23/2026Last Earnings8/13/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VYNE CIK1566044 Webvynetherapeutics.com Phone(800) 755-7936FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.48 million Net Margins-4,726.21% Pretax Margin-4,782.82% Return on Equity-70.42% Return on Assets-63.46% Debt Debt-to-Equity RatioN/A Current Ratio20.86 Quick Ratio20.86 Sales & Book Value Annual Sales$570 thousand Price / Sales33.29 Cash FlowN/A Price / Cash FlowN/A Book Value$41.71 per share Price / Book0.68Miscellaneous Outstanding Shares670,000Free Float648,000Market Cap$18.98 million OptionableNot Optionable Beta2.00 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:VYNE) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredAI insiders stockpile guns, gold & gas masksKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredWho Really Gets Rich from IPOs?Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
